Cleerly
About Cleerly
Cleerly is a health tech company developing AI powered coronary imaging and analysis to improve cardiovascular disease detection and risk assessment from CT scans and related data.
Trend Decomposition
Trigger: Growing demand for non invasive, AI assisted cardiovascular diagnostics and early detection of coronary artery disease.
Behavior change: Clinicians increasingly rely on AI augmented imaging readouts to guide treatment decisions and risk stratification.
Enabler: Advances in AI software, validated imaging biomarkers, and cloud based platforms enabling scalable interpretation of CT angiography data.
Constraint removed: Reduced need for invasive diagnostic procedures and manual image analysis through automated, standardized scoring.
PESTLE Analysis
Political: Growing emphasis on value based care drives adoption of outcome focused imaging technologies.
Economic: AI enabled diagnostics have potential to reduce downstream costs via earlier intervention and reduced unnecessary procedures.
Social: Rising patient demand for non invasive, precise cardiovascular risk assessment and personalized treatment planning.
Technological: Advances in AI, computer vision, and imaging hardware enable automated plaque characterization and lesion scoring.
Legal: Regulatory pathways for medical AI require robust validation, data privacy, and clear liability delineation.
Environmental: Digital imaging reduces need for repeat imaging and travel, potentially lowering carbon footprint of diagnostics.
Jobs to be done framework
What problem does this trend help solve?
Improve accuracy and speed of coronary disease detection to enable earlier, more effective interventions.What workaround existed before?
Manual image interpretation by radiologists and cardiologists with limited standardization and potential inter reader variability.What outcome matters most?
Certainty and speed in diagnosis, followed by cost efficiency and improved patient outcomes.Consumer Trend canvas
Basic Need: Reliable, non invasive cardiovascular risk assessment.
Drivers of Change: AI capabilities, demand for non invasive diagnostics, and reimbursement incentives for value based care.
Emerging Consumer Needs: Transparent, explainable AI findings and faster diagnostic workflows.
New Consumer Expectations: Higher accuracy, shorter wait times, and integration with electronic health records.
Inspirations / Signals: Partnerships with major imaging vendors and healthcare providers leveraging AI for CAD.
Innovations Emerging: Automated plaque characterization, lesion level risk scoring, and cloud based collaboration tools.
Companies to watch
- Cleerly - AI powered coronary imaging and plaque analysis platform.
- Siemens Healthineers - Imaging hardware and AI enabled analytics for cardiovascular diagnostics.
- Philips Healthcare - Imaging systems and AI software for cardiovascular imaging.
- GE Healthcare - Medical imaging and AI powered diagnostic tools for cardiology.
- Zebra Medical Vision - AI imaging analytics across multiple modalities, including cardiology applications.
- HeartFlow - Non invasive FFRct analysis from CT to assess coronary flow restrictions.
- CardioDiagnostics - AI driven cardiovascular risk assessment and imaging analytics.
- Viz.ai - AI driven platform for neurovascular and cardiovascular imaging coordination.
- Arterys - Cloud based AI imaging platform with cardiovascular modules.
- Butterfly Network - Handheld ultrasound with AI assisted analysis impacting cardiovascular screening workflows.